Role of Serine Proteases and Host Cell Receptors Involved in Proteolytic Activation, Entry of SARS-CoV-2 and Its Current Therapeutic Options

References

• NITULEScU GM, PAUNEScU H, MOScHOS SA, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies. Int J Mol Med. 2020;46(2):467–488. doi:10.3892/ijmm.2020.460832468014
   PubMed Web of Science ®Google Scholar
• Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop. J Mol Biol. 2020;432(10):3309–3325.32320687
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141–1149. doi:10.1038/s41401-020-0485-432747721
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569. doi:10.1038/s41564-020-0688-y32094589
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;183(6):1735. doi:10.1016/j.cell.2020.11.03233306958
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Nat l Acad Sci. 2020;117(21):11727–11734. doi:10.1073/pnas.2003138117
   PubMed Web of Science ®Google Scholar
• Albini A, Noonan DM, Pelosi G, Di Guardo G, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor-and angiotensin II receptor blocker-based antihypertensive therapies—reply. Intern Emerg Med. 2020;1–2.
   Web of Science ®Google Scholar
• Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-632327758
   PubMed Web of Science ®Google Scholar
• Lu M, Uchil PD, Li W, et al. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. Cell Host Microbe. 2020;28(6):880–891. doi:10.1016/j.chom.2020.11.00133242391
   PubMed Web of Science ®Google Scholar
• Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically-sensitive activation loop. J Mol Biol. 2020;432(10):3309–3325.32320687
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Hofmann-Winkler H, Smith JC, et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine. 2021;65:103255. doi:10.1016/j.ebiom.2021.10325533676899
   PubMed Web of Science ®Google Scholar
• Rossi GA, Sacco O, Mancino E, Cristiani L, Midulla F. Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases. Infection. 2020;1–5.
   Web of Science ®Google Scholar
• Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020.
   Google Scholar
• Sivaraman H, Er SY, Choong YK, Gavor E, Sivaraman J. Structural Basis of SARS-CoV-2–and SARS-CoV–Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. Annu Rev Pharmacol Toxicol. 2020;61:61. doi:10.1146/annurev-pharmtox-061220-093932
   Web of Science ®Google Scholar
• Hörnich BF, Großkopf AK, Schlagowski S, et al. SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation. J Virol. 2021;95(9). doi:10.1128/JVI.00002-21.
   Web of Science ®Google Scholar
• Saghazadeh A, Rezaei N. Towards treatment planning of COVID-19: rationale and hypothesis for the use of multiple immunosuppressive agents: anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol. 2020;84:106560. doi:10.1016/j.intimp.2020.10656032413736
   PubMed Web of Science ®Google Scholar
• Hasan A, Paray BA, Hussain A, et al. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin. J Biomol Struct Dyn. 2020;1–9.
   Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacological Research. 2020;157:104859. doi:10.1016/j.phrs.2020.10485932360480
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.05232142651
   PubMed Web of Science ®Google Scholar
• Astuti I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metabol Syndr. 2020;14(4):407–412. doi:10.1016/j.dsx.2020.04.020
   PubMed Web of Science ®Google Scholar
• Yan T, Xiao R, Lin G. Angiotensin‐converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS‐CoV‐2: a double‐edged sword? FASEB J. 2020;34(5):6017–6026. doi:10.1096/fj.20200078232306452
   PubMed Web of Science ®Google Scholar
• Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2. J Med Virol. 2020;92(6):595–601. doi:10.1002/jmv.2572632100877
   PubMed Web of Science ®Google Scholar
• Huang J, Song W, Huang H, Sun Q. Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. J Clin Med. 2020;9(4):1131. doi:10.3390/jcm9041131
   Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-932125455
   PubMed Web of Science ®Google Scholar
• Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma* S-J. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin–angiotensin system. Eur Heart J Cardiovasc Pharmacother. 2020;6(5):317–325. doi:10.1093/ehjcvp/pvaa05332464637
   PubMed Web of Science ®Google Scholar
• Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):1–10. doi:10.1186/s13054-020-03120-031898531
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773–781. doi:10.1016/j.bbrc.2004.09.10615474494
   PubMed Web of Science ®Google Scholar
• Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol. 2020;17(6):621–630. doi:10.1038/s41423-020-0458-z32415260
   PubMed Web of Science ®Google Scholar
• He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol. 2005;174(8):4908–4915. doi:10.4049/jimmunol.174.8.490815814718
   PubMed Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect. 2020;80(5):554–562. doi:10.1016/j.jinf.2020.02.02632169481
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Baghdady AM, Ali SA, Ahmed MI. GRP78 targeting: hitting two birds with a stone. Life Sci. 2020;260:118317. doi:10.1016/j.lfs.2020.11831732841659
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, Köseler A, et al. Preliminary virtual screening studies to identify GRP78 inhibitors which may interfere with SARS-CoV-2 infection. Pharmaceuticals. 2020;13(6):132. doi:10.3390/ph13060132
   Web of Science ®Google Scholar
• Elfiky AA, Ibrahim IM, Ismail AM, Elshemey WM. A possible role for GRP78 in cross vaccination against COVID-19. J Infect. 2020.
   Web of Science ®Google Scholar
• Patel S, Srivastav AK, Gupta SK, et al. Carbon nanotubes for rapid capturing of SARS-COV-2 virus: revealing a mechanistic aspect of binding based on computational studies. RSC Adv. 2021;11(10):5785–5800. doi:10.1039/D0RA08888A
   Web of Science ®Google Scholar
• Arokiyaraj S, Stalin A, Kannan BS, Shin H. Geranii Herba as a Potential Inhibitor of SARS-CoV-2 Main 3CLpro, Spike RBD, and Regulation of Unfolded Protein Response: an In Silico Approach. Antibiotics. 2020;9(12):863. doi:10.3390/antibiotics9120863
   Web of Science ®Google Scholar
• Köseler A, Sabirli R, Gören T, Türkçüer I, Kurt Ö. Endoplasmic reticulum stress markers in SARS-COV-2 infection and pneumonia: case-control study. vivo. 2020;34(3 suppl):1645–1650. doi:10.21873/invivo.11956
   PubMed Web of Science ®Google Scholar
• Law JN, Tasnina N, Kshirsagar M, et al. Identifying Human interactors of SARS-CoV-2 proteins and drug targets for COVID-19 using network-based label propagation. arXiv preprint arXiv:200601968. 2020.
   Google Scholar
• Gelman R, Bayatra A, Kessler A, Schwartz A, Ilan Y. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. Emerging MicrobesInfect. 2020;1–21.
   Google Scholar
• Quimque MTJ, Notarte KIR, Fernandez RAT. et al. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms. J Biomol Struct Dyn;2020. 1–18. doi:10.1080/07391102.2020.1776639
   Web of Science ®Google Scholar
• Rayner JO, Roberts RA, Kim J, et al. AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication. Biochem Pharmacol. 2020;182:114227. doi:10.1016/j.bcp.2020.11422732966814
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78(4):779–784.e5. doi:10.1016/j.molcel.2020.04.02232362314
   PubMed Web of Science ®Google Scholar
• Nersisyan S, Shkurnikov M, Turchinovich A, Knyazev E, Tonevitsky A. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. PLoS One. 2020;15(7):e0235987. doi:10.1371/journal.pone.023598732726325
   PubMed Web of Science ®Google Scholar
• Uludağ H, Parent K, Aliabadi HM, Haddadi A. Prospects for RNAi therapy of COVID-19. Front Bioeng Biotechnol. 2020;8:916. doi:10.3389/fbioe.2020.0091632850752
   PubMed Web of Science ®Google Scholar
• Simmons G, Zmora P, Gierer S, Heurich A, Pöhlmann S. Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 2013;100(3):605–614. doi:10.1016/j.antiviral.2013.09.02824121034
   PubMed Web of Science ®Google Scholar
• Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293–1307. doi:10.1128/JVI.02202-1324227843
   PubMed Web of Science ®Google Scholar
• Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1–10. doi:10.1016/j.biochi.2017.07.01628778717
   PubMed Web of Science ®Google Scholar
• Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res. 2020;178:104792. doi:10.1016/j.antiviral.2020.10479232272173
   PubMed Web of Science ®Google Scholar
• Jaimes JA, Millet JK, Whittaker GR. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. Iscience. 2020;23(6):101212. doi:10.1016/j.isci.2020.10121232512386
   PubMed Web of Science ®Google Scholar
• Tang T, Jaimes JA, Bidon MK, Straus MR, Daniel S, Whittaker GR. Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin. ACS Infect Dis. 2021;7(2):264–272. doi:10.1021/acsinfecdis.0c0070133432808
   PubMed Web of Science ®Google Scholar
• Padmanabhan P, Desikan R, Dixit N Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. 2020.
   Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1–12. doi:10.1038/s41467-020-15562-931911652
   PubMed Web of Science ®Google Scholar
• Sasaki M, Uemura K, Sato A, et al. SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 2021;17(1):e1009233. doi:10.1371/journal.ppat.100923333476327
   PubMed Web of Science ®Google Scholar
• Katopodis P, Anikin V, Randeva HS, et al. Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. Int J Oncol. 2020;57(2):533–539. doi:10.3892/ijo.2020.507132468052
   PubMed Web of Science ®Google Scholar
• Bittmann S, Weissenstein A, Villalon G, Moschuring-Alieva E, Luchter E. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor? J Clin Med Res. 2020;12(5):320. doi:10.14740/jocmr416132489508
   PubMedGoogle Scholar
• Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Advances. 2020;6(50):eabe0751. doi:10.1126/sciadv.abe075133158912
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134. doi:10.1016/j.virusres.2014.11.02125445340
   PubMed Web of Science ®Google Scholar
• Ganesan SK, Venkatratnam P, Mahendra J, Devarajan N. Increased mortality of COVID-19 infected diabetes patients: role of furin proteases. Int J Obes. 2020;1–3.
   Web of Science ®Google Scholar
• Vankadari N. Structural interactions between pandemic SARS-CoV-2 spike glycoprotein and human Furin protease. bioRxiv. 2020.
   Google Scholar
• Anand P, Puranik A, Aravamudan M, Venkatakrishnan A, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. Elife. 2020;9:e58603. doi:10.7554/eLife.5860332452762
   PubMed Web of Science ®Google Scholar
• Papa G, Mallery DL, Albecka A, et al. Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion. PLoS Pathog. 2021;17(1):e1009246. doi:10.1371/journal.ppat.100924633493182
   PubMed Web of Science ®Google Scholar
• Tang T, Jaimes JA, Bidon MK, Straus MR, Daniel S, Whittaker GR. Proteolytic activation of the SARS-CoV-2 spike S1/S2 site: a re-evaluation of furin cleavage. bioRxiv. 2020.
   Google Scholar
• Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Scialliance. 2020;3(9):9. doi:10.26508/lsa.202000786
   Web of Science ®Google Scholar
• Örd M, Faustova I, Loog M. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV. Sci Rep. 2020;10(1):1–10. doi:10.1038/s41598-020-74101-031913322
   PubMed Web of Science ®Google Scholar
• Cheng Y-W, Chao T-L, Li C-L, et al. Furin Inhibitors Block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;33(2):108254. doi:10.1016/j.celrep.2020.10825433007239
   PubMed Web of Science ®Google Scholar
• Artigas L, Coma M, Matos-Filipe P, et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS One. 2020;15(10):e0240149. doi:10.1371/journal.pone.024014933006999
   PubMed Web of Science ®Google Scholar
• Aoe T. Pathological aspects of COVID-19 as a conformational disease and the use of pharmacological chaperones as a potential therapeutic strategy. Front Pharmacol. 2020;11:1095. doi:10.3389/fphar.2020.0109532754041
   PubMed Web of Science ®Google Scholar
• Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: a case-control study. Life Sci. 2020;265:118781. doi:10.1016/j.lfs.2020.11878133220289
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li J, Pang Z. Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development. Asian J Pharm Sci. 2020.
   Web of Science ®Google Scholar
• Allam L, Ghrifi F, Mohammed H, et al. Targeting the GRP78-Dependant SARS-CoV-2 cell entry by peptides and small molecules. Bioinform Biol Insights. 2020;14:1177932220965505. doi:10.1177/117793222096550533149560
   PubMed Web of Science ®Google Scholar
• Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020.
   Web of Science ®Google Scholar
• Xu J, Teng Y, Shang L, et al. The effect of prior ACEI/ARB treatment on COVID-19 susceptibility and outcome: a systematic review and meta-analysis. Clin Infect Dis. 2020.
   Google Scholar
• Amin SA, Jha T. Fight against novel coronavirus: a perspective of medicinal chemists. Eur J Med Chem. 2020;201:112559. doi:10.1016/j.ejmech.2020.11255932563814
   PubMed Web of Science ®Google Scholar
• Goel N, Bhyan SJ, Bhyan B, Jain A, Kumari A, Sharma G. The Role of ACE2 Receptor and its Age Related Immunity in Covid-19.
   Google Scholar
• Chaudhry SN, Hazafa A, Mumtaz M, et al. New insight on possible vaccine development against SARS-CoV-2. Life Sci. 2020;260:118421. doi:10.1016/j.lfs.2020.11842132926920
   PubMed Web of Science ®Google Scholar
• Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–811. doi:10.1126/science.abc628432434945
   PubMed Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589. doi:10.1016/j.immuni.2020.03.00732259480
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332. doi:10.1056/NEJMoa202692032877576
   PubMed Web of Science ®Google Scholar
• Leach DA, Isac A-M, Bevan CL, Brooke GN. TMPRSS2, required for SARS-CoV-2 entry, is downregulated in lung cells by enzalutamide, a prostate cancer therapeutic. 2020.
   Google Scholar
• Shetty R, Ghosh A, Honavar SG, Khamar P, Sethu S. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future. Indian J Ophthalmol. 2020;68(5):693. doi:10.4103/ijo.IJO_639_2032317431
   PubMed Web of Science ®Google Scholar
• Bilal M, Iqbal HM. Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2. Hum Vaccin Immunother. 2020;1–9.
   Web of Science ®Google Scholar
• Samrat SK, Tharappel AM, Li Z, Li H. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res. 2020;198141.32846196
   PubMed Web of Science ®Google Scholar
• Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov. 2020;10(6):779–782. doi:10.1158/2159-8290.CD-20-045132276929
   PubMed Web of Science ®Google Scholar
• Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med. 2020;1–2.
   PubMed Web of Science ®Google Scholar
• Sternberg A, McKee DL, Naujokat C. Novel drugs targeting the SARS-CoV-2/COVID-19 machinery. Curr Top Med Chem. 2020;20(16):1423–1433. doi:10.2174/156802662099920051704313732416679
   PubMed Web of Science ®Google Scholar
• Breining P, Frølund AL, Højen JF, et al. Camostat mesylate against SARS‐CoV‐2 and COVID‐19–rationale, dosing and safety. Basic Clin Pharmacol Toxicol. 2020.
   Web of Science ®Google Scholar
• Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID‐19: what’s next? Br J Pharmacol. 2020;177(21):4813–4824. doi:10.1111/bph.1507232329520
   PubMed Web of Science ®Google Scholar
• Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol. 2020;1–8.
   Web of Science ®Google Scholar
• Wambier CG, Goren A, Vaño‐Galván S, et al. Androgen sensitivity gateway to COVID −19 disease severity. Drug Dev Res. 2020;81(7):771–776. doi:10.1002/ddr.2168832412125
   PubMed Web of Science ®Google Scholar
• Qing E, Gallagher T. SARS coronavirus redux. Trends Immunol. 2020;41(4):271–273. doi:10.1016/j.it.2020.02.00732173256
   PubMed Web of Science ®Google Scholar
• Zang R, Castro MFG, McCune BT, et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(47):47. doi:10.1126/sciimmunol.abc3582
   Web of Science ®Google Scholar